Instil Bio子公司终止Axn-2510临床开发 解除与ImmuneOnco合作协议

美股速递
Jan 06

Instil Bio旗下子公司正式宣布,将全面停止肿瘤治疗药物Axn-2510的临床研发计划。与此同时,该公司已与生物技术企业ImmuneOnco达成一致,双方共同终止此前签署的授权及合作协议。这一决定标志着双方在Axn-2510项目上的合作正式画上句号。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10